Sumitomo Pharma Co., Ltd. (DNPUF)
DNPUF Stock Price Chart
Explore Sumitomo Pharma Co., Ltd. interactive price chart. Choose custom timeframes to analyze DNPUF price movements and trends.
DNPUF Company Profile
Discover essential business fundamentals and corporate details for Sumitomo Pharma Co., Ltd. (DNPUF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
17 Jan 2012
Employees
4.98K
Website
https://www.sumitomo-pharma.comCEO
Toru Kimura
Description
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
DNPUF Financial Timeline
Browse a chronological timeline of Sumitomo Pharma Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 29 Jan 2026
Upcoming earnings on 31 Oct 2025
Revenue estimate is $725.17M.
Earnings released on 31 Jul 2025
EPS came in at $0.20 surpassing the estimated $0.14 by +43.06%, while revenue for the quarter reached $749.43M , beating expectations by +48.03%.
Earnings released on 13 May 2025
EPS came in at $0.04 surpassing the estimated -$0.08 by +150.90%, while revenue for the quarter reached $726.44M , beating expectations by +28.41%.
Earnings released on 29 Jan 2025
EPS came in at $0.86 surpassing the estimated $0.26 by +225.48%, while revenue for the quarter reached $715.08M , beating expectations by +29.02%.
Earnings released on 30 Oct 2024
EPS came in at -$0.84 falling short of the estimated $0.12 by -775.80%, while revenue for the quarter reached $626.64M , beating expectations by +2.59%.
Earnings released on 31 Jul 2024
EPS came in at $0.25 surpassing the estimated -$0.07 by +480.68%, while revenue for the quarter reached $564.54M , beating expectations by +10.83%.
Earnings released on 14 May 2024
EPS came in at -$3.27 falling short of the estimated -$2.14 by -52.90%, while revenue for the quarter reached $524.26M , missing expectations by -1.38%.
Earnings released on 31 Jan 2024
EPS came in at -$0.90 falling short of the estimated -$0.41 by -119.13%, while revenue for the quarter reached $588.92M , missing expectations by -9.51%.
Earnings released on 30 Sept 2023
EPS came in at -$0.49 falling short of the estimated -$0.29 by -68.43%, while revenue for the quarter reached $514.96M , missing expectations by -12.28%.
Earnings released on 30 Jun 2023
EPS came in at -$0.68 falling short of the estimated -$0.28 by -145.24%, while revenue for the quarter reached $523.71M , missing expectations by -9.54%.
Earnings released on 31 Mar 2023
EPS came in at -$1.06 falling short of the estimated -$0.61 by -73.76%, while revenue for the quarter reached $719.07M , missing expectations by -5.43%.
Dividend declared on 30 Mar 2023
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 28 Jun 2023.
Earnings released on 31 Jan 2023
EPS came in at -$0.22 falling short of the estimated $0.27 by -179.71%, while revenue for the quarter reached $1.09B , missing expectations by -14.57%.
Earnings released on 31 Oct 2022
EPS came in at -$0.66 falling short of the estimated -$0.04 by -1.66K%, while revenue for the quarter reached $1.10B , beating expectations by +8.24%.
Dividend declared on 29 Sept 2022
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 1 Dec 2022.
Earnings released on 29 Jul 2022
EPS came in at $0.58 surpassing the estimated $0.15 by +291.39%, while revenue for the quarter reached $1.18B , beating expectations by +12.86%.
Earnings released on 13 May 2022
EPS came in at $0.20 surpassing the estimated $0.05 by +321.64%, while revenue for the quarter reached $1.05B , missing expectations by -1.89%.
Dividend declared on 30 Mar 2022
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 24 Jun 2022.
Earnings released on 31 Jan 2022
EPS came in at $0.22 falling short of the estimated $0.25 by -12.89%, while revenue for the quarter reached $1.20B , missing expectations by -1.64%.
Earnings released on 27 Oct 2021
EPS came in at $0.70 surpassing the estimated $0.38 by +84.92%, while revenue for the quarter reached $1.46B .
Dividend declared on 29 Sept 2021
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 1 Dec 2021.
Earnings released on 29 Jul 2021
EPS came in at $0.11 falling short of the estimated $0.42 by -73.67%, while revenue for the quarter reached $1.18B .
Earnings released on 12 May 2021
EPS came in at -$0.32 surpassing the estimated -$1.00 by +67.71%, while revenue for the quarter reached $1.10B .
Dividend declared on 30 Mar 2021
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 25 Jun 2021.
Earnings released on 28 Jan 2021
EPS came in at $0.80 surpassing the estimated $0.03 by +2.31K%, while revenue for the quarter reached $1.29B .
Earnings released on 28 Oct 2020
EPS came in at $0.46 surpassing the estimated $0.16 by +179.39%, while revenue for the quarter reached $1.21B , beating expectations by +254.90%.
Dividend declared on 29 Sept 2020
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 1 Dec 2020.
DNPUF Stock Performance
Access detailed DNPUF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.